Literature DB >> 25176967

Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?

Wim A Wuyts1, Alberto Cavazza1, Giulio Rossi1, Francesco Bonella1, Nicola Sverzellati1, Paolo Spagnolo2.   

Abstract

Idiopathic pulmonary fibrosis (IPF), the most common and lethal of the idiopathic interstitial pneumonias, is defined by a radiological and/or pathological pattern of usual interstitial pneumonia (UIP). However, UIP is not synonymous with IPF as other clinical conditions may be associated with UIP, including chronic hypersensitivity pneumonitis, collagen vascular disease, drug toxicity, asbestosis, familial IPF and Hermansky-Pudlak syndrome. Differentiating IPF ("idiopathic UIP") from conditions that mimic IPF ("secondary UIP") has substantial therapeutic and prognostic implications. A number of radiological and histological clues may help distinguish IPF from other conditions with a UIP pattern of fibrosis, but their appreciation requires extensive expertise in interstitial lung disease as well as an integrated multidisciplinary approach involving pulmonologists, radiologists and pathologists. In addition, multidisciplinary discussions may decrease the time to initial IPF diagnosis and, thus, enable more timely management. This concept was strongly emphasised by the 2011 ATS/ERS/JRS/ALAT guidelines. This article highlights, with the aid of a clinical case, the difficulties in making a diagnosis of IPF in clinical practice. Yet, an accurate diagnosis is critical, particularly given the availability of drugs that may reduce the pace of functional decline and disease progression in IPF. ©ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176967     DOI: 10.1183/09059180.00004914

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  25 in total

1.  Bronchial anthracofibrosis with interstitial lung disease: an association yet to be highlighted.

Authors:  Shekhar Kunal; Vikas Pilaniya; Ashok Shah
Journal:  BMJ Case Rep       Date:  2016-01-11

Review 2.  Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.

Authors:  Loka R Penke; Marc Peters-Golden
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

3.  Idiopathic pulmonary fibrosis can be a transient diagnosis.

Authors:  Martina Rodrigues de Oliveira; Daniel Antunes Silva Pereira; Olívia Meira Dias; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  J Bras Pneumol       Date:  2016 Jan-Feb       Impact factor: 2.624

4.  Interstitial Pneumonia With Autoimmune Features: Value of Histopathology.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Eleanor Valenzi; Cathryn Lee; Leah J Witt; Lena Chen; Steven Montner; Jonathan H Chung; Imre Noth; Rekha Vij; Mary E Strek; Aliya N Husain
Journal:  Arch Pathol Lab Med       Date:  2017-05-03       Impact factor: 5.534

Review 5.  Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.

Authors:  Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin
Journal:  Expert Rev Respir Med       Date:  2022-01-31       Impact factor: 3.772

6.  A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury.

Authors:  Merriline M Satyamitra; David R Cassatt; Libero Marzella
Journal:  Radiat Res       Date:  2022-04-01       Impact factor: 2.841

Review 7.  Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay.

Authors:  Stefano Palmucci; Federica Galioto; Giulia Fazio; Agata Ferlito; Giovanna Cancemi; Alessia Di Mari; Gianluca Sambataro; Domenico Sambataro; Giovanni Zanframundo; Letizia Antonella Mauro; Pietro Valerio Foti; Carlo Vancheri; Antonio Basile
Journal:  Insights Imaging       Date:  2022-06-29

Review 8.  Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.

Authors:  Paolo Spagnolo; Jonathan A Kropski; Mark G Jones; Joyce S Lee; Giulio Rossi; Theodoros Karampitsakos; Toby M Maher; Argyrios Tzouvelekis; Christopher J Ryerson
Journal:  Pharmacol Ther       Date:  2020-12-24       Impact factor: 13.400

Review 9.  Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis.

Authors:  Maria A Trawinska; Ruwani D Rupesinghe; Simon P Hart
Journal:  Ther Clin Risk Manag       Date:  2016-04-08       Impact factor: 2.423

Review 10.  The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.

Authors:  Lucy A Murtha; Michael J Schuliga; Nishani S Mabotuwana; Sean A Hardy; David W Waters; Janette K Burgess; Darryl A Knight; Andrew J Boyle
Journal:  Front Physiol       Date:  2017-10-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.